Zaloguj się

Gotowe bibliografie tematyczne / San jun yi zhang dui

Spis treści

Artykuły w czasopismach
Książki

Gotowa bibliografia na temat „San jun yi zhang dui”

Autor: Grafiati

Data publikacji: 27 lipca 2024

Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „San jun yi zhang dui”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "San jun yi zhang dui"

1

Ji, Yinghua, Honglan Qu, Feidu Zhou, et al. "Abstract PO2-16-08: Adjuvant Treatment Selection for County-Level Patients with HR+/HER2- Early Breast Cancer in a Real-Life Setting in China." Cancer Research 84, no. 9_Supplement (2024): PO2–16–08—PO2–16–08. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-16-08.

Pełny tekst źródła

Streszczenie:

Abstract Background: CHASE001 (NCT05544123), a prospective, non-interventional multicenter study exploring real-world treatment and referral behavior of Chinese county patients (pts) with HER2+ or HR+/HER2– breast cancer is ongoing since September 2022. A prespecified interim analysis (IA) on 750 HER2+ and HR+/HER2- early breast cancer (eBC) was reported at the ESMO Congress 2023. In the 2nd IA from CHASE001, adjuvant treatment selection for patients with HR+/HER2- eBC will be evaluated. Methods: The study was designed to enroll 2500 pts, including four cohorts (HER2+ eBC, HR+/HER2-eBC, HER2+

Style APA, Harvard, Vancouver, ISO itp.

2

Wan, Rui, Yi Fung Chau, Jun Zhao, et al. "Abstract CT055: Efficacy of YK-029A, a novel EGFR TKI, in advanced NSCLC patients with acquired T790M mutation." Cancer Research 84, no. 7_Supplement (2024): CT055. http://dx.doi.org/10.1158/1538-7445.am2024-ct055.

Pełny tekst źródła

Streszczenie:

Abstract In the multicenter, dose-escalation and dose-expansion phase 1 clinical trial (NCT05767866), we evaluated safety and tolerability of YK-029A in various EGFR mutated non-small-cell lung cancer (NSCLC). We have reported efficacy of YK-029A in untreated NSCLC with EGFR ex20ins mutation[1]. This time we report efficacy of YK-029A in patients with acquired EGFR T790M mutation after failure of first or second generation EGFR tyrosine kinase inhibitors (TKIs). Method: This dose-escalation and dose-expansion phase 1 trial recruited previously treated NSCLC patients with EGFR T790M mutation or

Style APA, Harvard, Vancouver, ISO itp.

3

Lin, Jia-Yi, Wei-Wei Zhang, Qing-Jie Li, et al. "Abstract 1113: USP18 impairs the sensitivity of radiotherapy for nasopharyngeal carcinoma by promoting the ubiquitination and nuclear translocation of TRIM29." Cancer Research 84, no. 6_Supplement (2024): 1113. http://dx.doi.org/10.1158/1538-7445.am2024-1113.

Pełny tekst źródła

Streszczenie:

Abstract Radiotherapy is the main and preferred treatment for nasopharyngeal carcinoma (NPC), owing to its high sensitivity to radiation. However, there are ~20% patients suffering from tumor recurrence. Accumulating evidences show that protein ubiquitination plays a vital role in radiation caused DNA damage response. Here, we identified that the deubiquitinase USP18 is highly expressed in NPC tissues, and inversely associated with radiosensitivity of NPC cells. USP18 interacts with TRIM29 and promotes its K27-linked ubiquitination independent of its deubiquitinase activity. Further investigat

Style APA, Harvard, Vancouver, ISO itp.

4

Shi, Qiyun, Xiaowei Qi, Peng Tang, et al. "Abstract OT2-22-01: Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial." Cancer Research 83, no. 5_Supplement (2023): OT2–22–01—OT2–22–01. http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-22-01.

Pełny tekst źródła

Streszczenie:

Abstract Background: Dual HER2 targeted therapy with pyrotinib (a tyrosine kinase inhibitor targeting HER1, HER2, and HER4) and trastuzumab plus chemotherapy has been approved as neoadjuvant therapy for patients with HER2-positive breast cancer in China based on the results from phase 3 PHEDRA study. However, the optimal chemotherapy partner still needs exploration. This multicenter phase 2 trial (ChiCTR1900022293) aimed to investigate the efficacy and safety of epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib (ECP-THP) as neoadjuvant therapy for pati

Style APA, Harvard, Vancouver, ISO itp.

5

Liang, Yan, Jing Liu, Tao Luo, et al. "Abstract P5-10-01: Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: efficacy, safety and biomarker analysis from the SWH-B006 (neoALTALL) trial." Cancer Research 83, no. 5_Supplement (2023): P5–10–01—P5–10–01. http://dx.doi.org/10.1158/1538-7445.sabcs22-p5-10-01.

Pełny tekst źródła

Streszczenie:

Abstract Background: Anlotinib, a novel multi-target tyrosine kinase inhibitor that effectively inhibits VEGFR, PDGFR, FGFR, c-KIT, c-MET, and RET, monotherapy has been proven effective in HER-2 negative metastatic breast cancer, but its efficacy in early-stage triple-negative breast cancer (TNBC) is unknown. This phase 2 study aims to evaluate the efficacy and safety of adding anlotinib to neoadjuvant chemotherapy in patients (pts) with primary TNBC. Methods: Pts with clinical stage II/III TNBC were to be treated with 5 cycles of anlotinib (12mg, d1-14, q3w) plus 6 cycles of taxanes (docetaxe

Style APA, Harvard, Vancouver, ISO itp.

6

Kim, Beom-Jun, Ze-Yi Zheng, Jonathan Lei, et al. "Abstract PO2-14-11: Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatment." Cancer Research 84, no. 9_Supplement (2024): PO2–14–11—PO2–14–11. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-14-11.

Pełny tekst źródła

Streszczenie:

Abstract NF1 is a key tumor suppressor that represses both RAS and estrogen receptor-α (ER) signaling in breast cancer. Blocking both pathways by fulvestrant (F), a selective ER degrader (SERD), together with binimetinib (B), a MEK inhibitor, promotes tumor regression in NF1-depleted ER+ models. We aimed to establish approaches to determine how NF1 protein levels impact B+F treatment response to improve our ability to identify B+F sensitive tumors. We examined a panel of ER+ PDX models by DNA and mRNA sequencing and found that more than half of these models carried an NF1 shallow deletion and

Style APA, Harvard, Vancouver, ISO itp.

7

Li, Yu-Wei, Ding Ma, Xiang-Rong Wu, et al. "Abstract PS09-09: Multiomics profiling and molecular classification refine precision treatment strategies for HER2-positive breast cancer." Cancer Research 84, no. 9_Supplement (2024): PS09–09—PS09–09. http://dx.doi.org/10.1158/1538-7445.sabcs23-ps09-09.

Pełny tekst źródła

Streszczenie:

Abstract Background: Anti-HER2 targeted therapy has achieved a series of breakthroughs. However, the current treatment strategy regarding HER2-positive breast cancer remains indiscriminate and lacks specificity, which limits the further improvement of overall treatment response and may lead to overtreatment and extra cost for some patients. Our study aims to reveal the molecular heterogeneity of HER2-positive breast cancer to guide a more precise treatment. Patients and methods: We selected HER2-positive breast cancer patients treated at Fudan University Shanghai Cancer Center between 2013 and

Style APA, Harvard, Vancouver, ISO itp.

8

Xie, Hui, Wei Li, Yufeng Yao, et al. "Abstract P2-13-41: First-line pyrotinib plus trastuzumab and nab-paclitaxel for patients with HER2-positive advanced breast cancer." Cancer Research 82, no. 4_Supplement (2022): P2–13–41—P2–13–41. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-13-41.

Pełny tekst źródła

Streszczenie:

Abstract Background: Overexpression of human epidermal factor receptor 2 (HER2) is seen in 15-20% of breast cancer and results in more aggressive clinical behavior and poor prognosis. This study (ChiCTR2000030618) analyzed the efficacy and safety of pyrotinib plus trastuzumab and nab-paclitaxel in patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer.Methods: Patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer received pyrotinib (400 mg, qd), trastuzumab (H, 8 mg/kg loading dose, followed by 6 mg/kg every 3 wee

Style APA, Harvard, Vancouver, ISO itp.

9

Shi, Qiyun, Juncheng Xuhong, Jia Ge, et al. "Abstract P5-13-31: Pik3ca mutations and myc amplification are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment." Cancer Research 82, no. 4_Supplement (2022): P5–13–31—P5–13–31. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-13-31.

Pełny tekst źródła

Streszczenie:

Abstract Background: Our previous study reported a good efficacy and safety of pyrotinib combined with trastuzumab neoadjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients. We further explored the potential biomarkers for the efficacy of pyrotinib combined with trastuzumab neoadjuvant treatment in HER2-positive breast cancer patients. Methods:To date, a total of 162 patients with early-stage breast cancer were enrolled for the neoadjuvant pyrotinib combined with trastuzumab treatment clinical trial (ChiCTR1900022293). By the method of 425 genes n

Style APA, Harvard, Vancouver, ISO itp.

10

Shi, Qiyun, Juncheng Xuhong, Hao Tian, Yi Zhang, Jun Jiang, and Xiaowei Qi. "Abstract P5-02-52: Predictive and prognosis value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors (TKIs): a systemic review and meta-analysis." Cancer Research 83, no. 5_Supplement (2023): P5–02–52—P5–02–52. http://dx.doi.org/10.1158/1538-7445.sabcs22-p5-02-52.

Pełny tekst źródła

Streszczenie:

Abstract Background: PIK3CA mutations is one of the most frequent gene alterations in breast cancers, which was reported to be related to the treatment response of anti-HER2 regimens. However, the relationship between PIK3CA mutations and treatment response of a tyrosine kinase inhibitors (TKIs) is still unclear. We thus conducted a systemic review and meta-analysis to investigate the predictive and prognosis value of PIK3CA mutations in HER2-positive breast cancer treated with TKIs. Methods: The following databases were searched from inception to July 2022: Medline, Embase and the Cochrane Li

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Książki na temat "San jun yi zhang dui"

1

1956-, Wallace David, and Wu Tianwei, eds. Qi san yi bu dui: Di er ci shi jie da zhan zhong de Riben xi jun zhan. Guo shi guan bian yin, 1992.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

1956-, Wallace David, and Wu Tianwei, eds. Qi san yi bu dui: Di er ci shi jie da zhan zhong di Riben xi jun zhan. Guo shi guan bian yin, 1992.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Zhu, Donald Knox, Liang Qing Yi, and Xia Jinbiao Yi, eds. San jiao zhou de jue qi: Mei jun san jiao zhou te zhong zuo zhan bu dui chuang shi ren hui yi lu = Delta force. Hua xue gong ye chu ban she, 2015.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Ou, Xiangjing. Yi dai yi lu, xi bu jue qi: "Shi san wu" shi qi Zhenning Buyizu Miaozu Zizhixian rong ru "yi dai yi lu" zhan lüe yan jiu. Xi nan jiao tong da xue chu ban she, 2016.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Guang zhou jun qu zheng zhi bu zu zhi bu. Yi xin qun: Mo fan shi jian"san ge dai biao"de xian jin zhan shi. Nan fang ri bao chu ban she, 2001.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Zhong gong zhong yang xuan chuan bu. Xi jin ping xin shi dai zhong guo te se she hui zhu yi si xiang san shi jiang. Xue xi chu ban she, 2018.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Heilongjiang Sheng wen wu kao gu yan jiu suo, ed. Qin Hua Ri jun di qi san yi bu dui jiu zhi: Xi jun shi yan shi ji te she jian yu kao gu fa jue bao gao. Ke xue chu ban she, 2018.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Weiwei, Ye, ed. San ge xin si jun nü bing de duo cai ren sheng: Hui yi mu qin Zhang Qian, Wang Yugeng, Ling Ben. Ren min chu ban she, 2011.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Zhaohong, Zheng, ed. Zou jin xin shi dai: Shi san jie si zhong quan hui yi lai dang de jian she ji shi. Shanxi ren min chu ban she, 2001.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Wei, Zhang, ed. 20 shi ji san si shi nian dai de Jin Shan nong cun she hui: Yi Zhang Wentian Jin Shan nong cun diao cha zi liao wei zhong xin de yan jiu. Zhongguo she hui ke xue chu ban she, 2010.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!